GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » Total Assets

Actinium Pharmaceuticals (STU:7AY1) Total Assets : €81.28 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals Total Assets?

Actinium Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €81.28 Mil.

During the past 12 months, Actinium Pharmaceuticals's average Total Assets Growth Rate was -42.80% per year. During the past 3 years, the average Total Assets Growth Rate was 18.90% per year. During the past 5 years, the average Total Assets Growth Rate was 29.60% per year. During the past 10 years, the average Total Assets Growth Rate was 28.00% per year.

During the past 13 years, Actinium Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 106.90%. The lowest was 3.30%. And the median was 23.90%.

Total Assets is connected with ROA %. Actinium Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -40.91%. Total Assets is also linked to Revenue through Asset Turnover. Actinium Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.


Actinium Pharmaceuticals Total Assets Historical Data

The historical data trend for Actinium Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals Total Assets Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.50 54.58 71.14 107.80 74.69

Actinium Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.29 91.42 83.34 74.69 81.28

Actinium Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Actinium Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=33.36+41.326
=74.69

Actinium Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=40.348+40.935
=81.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinium Pharmaceuticals  (STU:7AY1) Total Assets Explanation

Total Assets is connected with ROA %.

Actinium Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-31.904/( (74.685+81.284)/ 2 )
=-31.904/77.9845
=-40.91 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Actinium Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (74.685+81.284)/ 2 )
=0/77.9845
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Actinium Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals (STU:7AY1) Business Description

Traded in Other Exchanges
Address
275 Madison Avenue, 7th Floor, New York, NY, USA, 10016
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals (STU:7AY1) Headlines

No Headlines